Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 483 results for "ranbaxy laboratories"

Sun-Ranbaxy deal stirs monopoly concerns: CCI
Business Standard India

Ranbaxy Laboratories receives direction from CCI

Ranbaxy Laboratories has received direction vide letter dated August 27, 2014 from the Competition Commission of India(CCI) directing the Company to publish the details of the proposed combination in the prescribed format within 10 working days from the date ... Money Control, 6 days ago
[x]  

20 images for ranbaxy laboratories

4 Traders, 5 days ago
India TV, 3 weeks ago
Financial Express, 3 weeks ago
Times of India, 3 days ago
Financial Express, 1 month ago
Financial Express, 4 days ago
Financial Express, 1 month ago
Livemint.com, 1 month ago
Reuters India, 1 month ago
Business Today India, 3 weeks ago
Financial Express

RANBAXY LABORATORIES : Cci expands investigation into sun-ranbaxy deal

Sun Pharma and Ranbaxy had entered into a $4-billion deal in Apr 2014 to create the fifth largest speciality generics company in the world. The Competition Commission of India (CCI) has now directed the two companies to make public ...
 4 Traders19 hours ago CCI direction: Sun, Ranbaxy to publish details of merger  Hindu Business Line5 days ago Sun Pharma, Ranbaxy slip; CCI asks more details of merger  Moneycontrol.com5 days ago CCI expands its scrutiny into Sun-Ranbaxy deal  Economic Times6 days ago
[x]  
4 Traders

Surround Sound: What Indian Pharma can learn from Ranbaxy's Texas case

There are important lessons for the Indian generic-drug industry in the case involving Ranbaxy Laboratories in the Texas Medicaid Fraud Prevention Act. According to recent reports, Ranbaxy could face a fine to the tune of Rs 240 crore in a case ...
 InToday1 week ago Sun Pharma-Ranbaxy CCI probe in new phase [Mint, New Delhi :: ]  BusinessWeek5 days ago Moody's upbeat on India pharma sector; Lupin, Ranbaxy, Cipla hit fresh 52-week high  Economic Times1 week ago Ranbaxy Q1 net loss narrows  Individual.com2 weeks ago
[x]  
Rediff.com

Ranbaxy Laboratories Ltd clarifies on Rs. 242 crores fine

The Exchange had sought clarification with respect to the media report "Ranbaxy faces Rs.242 Crores fine in US for violations at Toansa" appearing in Business Standard on August 22, 2014. Ranbaxy Laboratories Ltd has clarified that, the Company is ...
 Equity Bulls1 week ago Another big blow for Ranbaxy  Rediff.com1 week ago Ranbaxy may face Rs 242 cr fine in US for violations at Toansa  Business Standard1 week ago Ranbaxy may have to pay Rs 242 crore fine in US  Business Standard India1 week ago
[x]  

Ranbaxy now a mid-cap stock

Ranbaxy Laboratories, which was the country's largest pharmaceutical company in terms of FY14 sales numbers, will figure in the CNX mid-cap index from September 26. Until March this year, the company was part of the benchmark Nifty index. The ...
 Smart Investor2 days ago Adani, RCom to opt out of Nifty mid-cap  Times of India1 week ago
NDTV Profit

RANBAXY LABORATORIES : may face another hefty fine in the US of Rs 240 crore

NEW DELHI : Ranbaxy Laboratories may have to pay another hefty fine in the United States of close to Rs 240 crore , this time imposed by the State of Texas , people familiar with the matter told ET. The company has been in negotiation with the US ...
 4 Traders5 days ago RANBAXY LABORATORIES : FACING Rs240 CRORE FINE IN TEXAS  4 Traders1 week ago Ranbaxy Labs slides on buzz of Rs 240 crore fine in US  Capital Market1 week ago Ranbaxy Laboratories may face another hefty fine in the US of Rs 240 crore  Economic Times1 week ago
[x]  
Business Standard India

Ranbaxy hits 52-week high on UBS upgrade

MUMBAI: Shares of Ranbaxy Laboratories gained momentum for fourth consecutive session to hit 52-week high after UBS raised its target price. According to the brokerage, the stock is a cheaper way to buy Sun Pharmaceuticals. It will benefit from ...
 Economic Times1 week ago Ranbaxy signs licensing agreement with Cipher for anti-acne therapy in Brazil  Individual.com1 month ago Ranbaxy hits 52-week high in volatile trade  Capital Market1 month ago Ranbaxy inks pact with cipher to sell acne drug  4 Traders1 month ago
[x]  

Cipla, TCS, Ranbaxy, Polaris to get astro support: Gupta

Pharma stocks like Cipla, Glenmark Pharma, Biocon, Divis Labs and Ranbaxy Laboratories to get astrological support, says Satish Gupta of astrostocktips.in.
 Money Control1 week ago Dr Reddy's, Glenmark, Ranbaxy to get astro support: Gupta  Money Control1 month ago Biocon, Bata, Dr Reddy's Labs to get astro support: Gupta  Money Control1 month ago
Business Standard India

Ranbaxy Laboratories hits record high, UBS ups target to Rs 784

Ranbaxy Laboratories has gained 1.5% to Rs 655, also its record high on National Stock Exchange (NSE), on reports that UBS has maintained buy rating on the stock with a target price of Rs 784 per share. The target price is 21% higher than Friday's ...
 Business Standard India1 week ago Ranbaxy hits record high, UBS raises target to Rs 784  Smart Investor1 week ago
4 Traders

Ranbaxy faces Rs 240cr fine in US

MUMBAI : Ranbaxy Laboratories will reportedly need to cough up a Rs 240 crore fine to the US authorities due to violations found at its active pharmaceutical Ingredient (API) manufacturing factory in Toansa, Punjab. The US FDA had banned the ...
 4 Traders5 days ago Bitter pill gets bitterer: Ranbaxy faces Rs 240-cr US fine  Moneycontrol.com1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy laboratories
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less